Search results
Results From The WOW.Com Content Network
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [13]
As of March 2021 the vaccine active substance (ChAdOx1-SARS-COV-2) was being produced at several sites worldwide, [86] with AstraZeneca claiming to have established 25 sites in 15 countries. [87] [needs update] The UK sites at that time were Oxford and Keele, with bottling and finishing in Wrexham.
APS – TEVA UK Ltd; Assertio – Assertio Therapeutics, Inc; AstraZeneca – AstraZeneca UK Limited; Aventis Pharma – Sanofi-Aventis Ltd; Bausch & Lomb – Bausch & Lomb UK Ltd; Baxter – Baxter International; Baxter BioScience – Baxter International; Bayer – Bayer plc (Pharmaceutical Division) Becton Dickinson – Becton Dickinson UK Ltd
British finance minister Rachel Reeves wants to reduce state provisions to the company's vaccine centre, which will cut the pledge made by the previous administration from about 90 million pounds ...
Drug Discovery company C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca plc (NASDAQ: AZN) worth up to $402 million for its NRF2 Activator program.
AstraZeneca on Friday said it was prioritizing the U.S. market for additional doses of its respiratory syncytial virus (RSV) drug Beyfortus, which was approved in July to prevent the disease in ...
New guidance for allergy sufferers, antibody tests, new variants of SARS-CoV-2 (B.1.1.7 and B.1.617) and the use of the AstraZeneca vaccine in younger adults have been issued throughout the programme. The programme also includes procurement of vaccines for British Overseas Territories and Crown Dependencies. [13] [14]
“We are pleased that as a leader in Oncology, AstraZeneca recognizes the scientific value of our TRACERx and MAP assets,” said Dr Iraj Ali, CEO of Achilles Therapeutics. “We believe that these assets have the potential to positively impact Oncology R&D and will support the development of new and improved therapies for cancer patients.”